Harvest Investment Advisors LLC Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)

Harvest Investment Advisors LLC increased its stake in Bristol-Myers Squibb (NYSE:BMY) by 3.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 30,255 shares of the biopharmaceutical company’s stock after acquiring an additional 1,075 shares during the period. Harvest Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,565,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. PYA Waltman Capital LLC bought a new stake in Bristol-Myers Squibb in the third quarter worth $203,000. Geller Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 19.1% in the third quarter. Geller Advisors LLC now owns 5,976 shares of the biopharmaceutical company’s stock valued at $309,000 after acquiring an additional 958 shares during the period. Nomura Asset Management Co. Ltd. lifted its holdings in shares of Bristol-Myers Squibb by 23.4% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 1,284,144 shares of the biopharmaceutical company’s stock worth $66,442,000 after acquiring an additional 243,108 shares during the last quarter. MML Investors Services LLC boosted its stake in shares of Bristol-Myers Squibb by 1.5% during the 3rd quarter. MML Investors Services LLC now owns 313,688 shares of the biopharmaceutical company’s stock worth $16,230,000 after purchasing an additional 4,554 shares during the period. Finally, Dunhill Financial LLC grew its holdings in Bristol-Myers Squibb by 39.8% during the 3rd quarter. Dunhill Financial LLC now owns 664 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 189 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Up 0.9 %

Shares of BMY stock opened at $59.38 on Monday. The stock’s fifty day moving average price is $55.48 and its 200 day moving average price is $48.83. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.00 earnings per share. Sell-side analysts anticipate that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.04%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb’s payout ratio is -66.85%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BMY shares. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Barclays lifted their target price on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a research report on Monday, October 7th. Citigroup upped their price target on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, November 12th. Finally, Jefferies Financial Group boosted their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research report on Wednesday, August 28th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $54.07.

Insider Buying and Selling

In related news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Samit Hirawat acquired 1,830 shares of Bristol-Myers Squibb stock in a transaction on Friday, November 1st. The shares were bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.